This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients.
Patients with newly diagnosed, histologically confirmed, non-metastatic, HR-PCa who are scheduled to receive RALP will be eligible to participate in the study.
Subjects must have biopsy-confirmed adenocarcinoma of the prostate.
Subjects must have a negative bone scan and CT scan or PSMA-PET for nodal or metastatic disease.
PSA ≥20 and/or
Gleason score ≥8 and/or
Metastatic disease as demonstrated by bone scan, CT scan, MRI of the pelvis, or PSMA-PET.
Declared high-risk for anesthesia by attending cardiologist, or other physician.
History of prior pelvic radiation therapy.
Prostate gland >70 cc as assessed by MRI or TRUS.